Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
ID: 357737Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $300K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357737

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-25-004.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)." This grant aims to support exploratory research projects that focus on the development and validation of innovative technologies to enhance the quality and handling of cancer-relevant biospecimens, addressing significant gaps in cancer research methodologies. The initiative is part of the National Cancer Institute's (NCI) broader Innovative Molecular Analysis Technologies (IMAT) Program, which seeks to improve cancer biology research, early detection, clinical diagnosis, and treatment, while also tackling health disparities. Eligible applicants can receive up to $300,000 per year for a maximum of three years, with a submission deadline of October 3, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-25-004.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-CA-25-004-Full-Announcement.html
    RFA-CA-25-004.html
    The National Cancer Institute (NCI) is issuing a Notice of Funding Opportunity (NOFO) to advance the development and validation of innovative biospecimen science technologies for cancer research. The funding, under the Exploratory/Developmental Grants Phase II (R33), aims to support projects that enhance the quality and handling of cancer-relevant samples, with a focus on technologies that improve biospecimen integrity and address significant gaps in cancer research methodologies. Applications should demonstrate preliminary success in the relevant technologies and must include rigorous validation plans. The NCI seeks to identify effective strategies in cancer risk reduction, early diagnosis, treatment, and health disparities. Funded projects may receive up to $300,000 per year for a maximum of three years, with an estimated total of $900,000 available for fiscal year 2026. Applicants are encouraged to submit their proposals electronically through the Grants.gov platform. The deadline for submissions is October 4, 2025, with the aim of supporting transformative research to improve clinical cancer care and outcomes. Compliance with the NIH Grants Policy Statement and related regulations is mandatory throughout the application process.
    Similar Opportunities
    Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)." This funding aims to support innovative projects that develop technologies for analyzing and managing biospecimens in cancer research and clinical care, with a focus on proof-of-concept studies that demonstrate feasibility in areas such as cancer biology, early detection, and health disparities. The total estimated program funding is $4.7 million, with individual awards ranging from $50,000 to $150,000, and approximately 17 awards are expected to be made. Interested applicants can reach out to Dr. Kelly Crotty at Kelly.crotty@nih.gov or by phone at 240-255-0917 for further information, with applications due by April 10, 2026.
    Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Integrating Biospecimen Science Approaches into Clinical Assay Development" (FON: PAR-25-325). This initiative aims to support extramural research focused on addressing preanalytical variability in the development and analytical validation of clinical assays utilizing biospecimens such as tumor biopsies and liquid biopsies. The program seeks to enhance the reliability of biomarker assays by investigating how various collection, processing, and storage conditions impact biomarker quantification, ultimately contributing to improved cancer diagnostics and treatment in precision medicine. Interested applicants can apply for funding of up to $250,000 annually for a period of five years, with the first application deadline set for January 4, 2025. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-325.html.
    Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity for R01 grant applications focused on the integration of imaging and fluid-based tumor monitoring in cancer therapy. The objective is to enhance research designs that utilize imaging and liquid biopsy assays to assess treatment responses and the emergence of resistance in cancer patients, thereby advancing precision medicine in cancer treatment. This initiative is critical for improving diagnostic techniques and patient monitoring strategies across various cancer types. Eligible applicants, including universities, for-profit organizations, and nonprofits, can apply for grants with a maximum budget of $500,000 per year for projects lasting up to five years. Applications will be accepted from January 5, 2025, until January 8, 2028, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants," aimed at accelerating the clinical validation of biomarker assays for cancer detection, diagnosis, prognosis, and treatment response. This initiative encourages multidisciplinary collaboration among researchers, clinicians, and statisticians, focusing on assays that have nearly completed analytical validation and utilize human specimens. The funding amount is capped at $150,000 per year for a maximum duration of three years, with application deadlines starting from January 14, 2025, and concluding on October 15, 2026. Interested applicants can find more information and guidelines at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Assay Validation of High Quality Markers for Clinical Studies in Cancer," aimed at enhancing the validation and adoption of biomarkers and assays critical for cancer detection, diagnosis, and treatment response prediction. This initiative seeks projects that utilize established assays with demonstrated analytical validation for clinical use, fostering collaboration among scientific experts to address significant gaps in cancer research. The funding amount is capped at $250,000 per year for a project duration of up to three years, with applications due by October 14, 2026. Interested applicants can find more information and application details at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the NCI Small Grants Program for Cancer Research (R03) for the years 2023 to 2025. This funding opportunity is designed to support small-scale research projects on cancer that can be completed within a two-year timeframe and with limited resources, including pilot studies, secondary data analyses, and the development of research methodologies or technologies. Grants of up to $50,000 per year are available to a wide range of eligible applicants, including higher education institutions, nonprofits, and various community organizations. Interested parties should submit their applications electronically via Grants.gov, with the first submission deadline having been January 22, 2023, and subsequent deadlines continuing through 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NCI Small Grants Program for Cancer Research (NCI Omnibus) (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the NCI Small Grants Program for Cancer Research (R03), aimed at supporting short-term cancer research projects that require limited resources. This funding opportunity encourages diverse research efforts, including pilot studies, secondary data analyses, and the development of research methodologies, with a maximum budget of $50,000 per year for projects lasting up to two years. The program is designed to address significant knowledge gaps in cancer research and is open to a wide range of applicants, including public, private, and foreign entities. Interested parties should note that the application period opens on January 24, 2025, with a submission deadline of February 24, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)" aimed at advancing research in cancer biology and oncology through the application of nanotechnology. This initiative encourages proposals that address significant challenges in these fields by focusing on mechanistic studies of nanomaterial interactions with biological systems, rather than clinical applications. The program is particularly important for enhancing the understanding of nanoparticle delivery mechanisms and improving diagnostic technologies in cancer treatment. Interested applicants can apply for grants with a budget cap of $475,000 per year over a maximum project period of five years, with applications due by May 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-246.html.
    Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Assay Validation of High Quality Markers for Clinical Studies in Cancer," aimed at supporting the validation of molecular, cellular, and imaging markers for cancer detection, diagnosis, and treatment. This initiative encompasses a two-phase cooperative agreement mechanism: the UH2 phase focuses on analytical validation of assays over a two-year period, while the UH3 phase supports clinical validation for up to three years, utilizing well-annotated biospecimens from clinical trials. The program emphasizes the importance of multidisciplinary collaboration to enhance the development of assays that can significantly improve cancer research and patient care. Eligible applicants include various institutions and organizations, with a funding ceiling of $275,000 for the UH2 phase and up to $250,000 per year for the UH3 phase. Applications will be accepted starting January 19, 2024, with a final submission deadline of October 15, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Assay Validation of High Quality Markers for Clinical Studies in Cancer" through a cooperative agreement mechanism (UH2/UH3). This initiative aims to support the validation of molecular, cellular, and imaging biomarkers essential for cancer detection, diagnosis, prognosis, and treatment response monitoring, with a focus on both analytical and clinical validation phases. The funding is intended for projects that demonstrate a working assay on human samples and justify its clinical relevance, fostering multi-disciplinary collaborations among scientific investigators, oncologists, and clinical laboratory scientists. Interested applicants should note that the application deadline is October 14, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-074.html.